InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
Our credit view of this issuer reflects its good free cash flow prior to any generic Xifaxan launch, offset by its high financial leverage and untenable capital structure.
Our credit view of this issuer reflects its good free cash flow prior to any generic XIfaxan launch, offset by its high financial leverage and untenable capital structure.
Our credit view of this issuer reflects its good free cash flow prior to any generic XIfaxan launch, offset by its high financial leverage and untenable capital structure.
Our credit view of this issuer reflects its high financial leverage and untenable capital structure given risks related to potential Xifaxan generic competition
Our credit view of this issuer reflects high potential for debt restructuring deemed to be a distress exchange, the potential genericization of Xifaxan, and high financial leverage.
Our credit view of this issuer reflects its large global scale and good margins, tempered by high financial leverage and exposure to generic competition on its largest drug
Our credit view of this issuer reflects its status as a large specialty pharmaceutical and healthcare company with strong product diversity, constrained by its high financial leverage.